Dr. Firas G. Petros
Claim this profileUniversity of Toledo
Studies Prostate Cancer
Studies Vulval Intraepithelial Neoplasia
4 reported clinical trials
22 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
synaptophysin positive
chromogranin positive
2Vulval Intraepithelial Neoplasia
Affiliated Hospitals
Clinical Trials Firas G. Petros is currently running
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria
More about Firas G. Petros
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Firas G. Petros has experience with
- CG0070
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Avelumab
- Axitinib
Breakdown of trials Firas G. Petros has run
Prostate Cancer
Vulval Intraepithelial Neoplasia
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Firas G. Petros specialize in?
Firas G. Petros focuses on Prostate Cancer and Vulval Intraepithelial Neoplasia. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are synaptophysin positive.
Is Firas G. Petros currently recruiting for clinical trials?
Yes, Firas G. Petros is currently recruiting for 2 clinical trials in Toledo Ohio. If you're interested in participating, you should apply.
Are there any treatments that Firas G. Petros has studied deeply?
Yes, Firas G. Petros has studied treatments such as CG0070, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Firas G. Petros?
Apply for one of the trials that Firas G. Petros is conducting.
What is the office address of Firas G. Petros?
The office of Firas G. Petros is located at: University of Toledo, Toledo, Ohio 43614 United States. This is the address for their practice at the University of Toledo.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.